Literature DB >> 31373245

Cognitive and mood side effects of lower urinary tract medication.

A Elif Muderrisoglu1, Klaus F Becher2, Stephan Madersbacher3, Martin C Michel4.   

Abstract

Introduction: Muscarinic receptor antagonists, 5α-reductase inhibitors and α1-adrenoceptor antagonists are frequently used drug classes for the treatment of lower urinary tract symptoms including those of overactive bladder syndrome and benign prostatic enlargement/benign prostatic obstruction. Areas covered: The authors review the evidence for adverse effects of these drug classes on cognitive function, mood and other functions of the central nervous system and discuss such effects against the evidence for mechanistic plausibility. Expert opinion: Muscarinic antagonists carry a risk for impaired cognition and other brain functions that differs quantitatively between compounds, being highest with oral formulations of oxybutynin. 5□-Reductase inhibitors can cause depressive symptoms even at low doses and starting several months after discontinuation of treatment. The evidence for α1-adrenoceptor antagonists and specifically tamsulosin to cause dementia is controversial and lacks mechanistic plausibility. We recommend that physicians treating patients with lower urinary tract symptoms carefully monitor mental status prior to prescribing and periodically thereafter.

Entities:  

Keywords:  5α-reductase inhibitors; cognitive impairment; depression; muscarinic receptor antagonists; α-adrenoceptor antagonists

Mesh:

Substances:

Year:  2019        PMID: 31373245     DOI: 10.1080/14740338.2019.1652269

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  5 in total

1.  Managing Nocturia in Frail Older Adults.

Authors:  Dylan T Wolff; Kerry A Adler; Corey S Weinstein; Jeffrey P Weiss
Journal:  Drugs Aging       Date:  2020-11-24       Impact factor: 3.923

Review 2.  [Short version of the S2k guideline on drug therapy of neurogenic lower urinary tract dysfunction (NLUTD)].

Authors:  J Kutzenberger; A Angermund; B Domurath; S Möhr; J Pretzer; I Soljanik; R Kirschner-Hermanns
Journal:  Urologie       Date:  2022-10-21

3.  Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis.

Authors:  Christos Andronis; João Pedro Silva; Eftychia Lekka; Vassilis Virvilis; Helena Carmo; Konstantina Bampali; Margot Ernst; Yang Hu; Irena Loryan; Jacques Richard; Félix Carvalho; Miroslav M Savić
Journal:  Arch Toxicol       Date:  2020-06-05       Impact factor: 5.153

4.  Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea.

Authors:  Bora Yeon; Ah Young Suh; Eunmi Choi; Bonggi Kim; Eunsun Noh; Soo Youn Chung; Soon Young Han
Journal:  PLoS One       Date:  2022-03-16       Impact factor: 3.240

5.  Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.

Authors:  Salvatore D'Agate; Chandrashekhar Chavan; Michael Manyak; Juan Manuel Palacios-Moreno; Matthias Oelke; Martin C Michel; Claus G Roehrborn; Oscar Della Pasqua
Journal:  World J Urol       Date:  2020-12-18       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.